Education
About Us
Working with TipRanks
Follow Us
PINK - ETF AI Analysis
Top Page
Simplify Health Care ETF (PINK)
Rating:65Neutral
Price Target:―
Positive Factors
Strong Sector Focus
The ETF is heavily weighted in the health care sector, which has shown resilience and steady growth over time.
Healthy Performance
The fund has delivered strong returns over the past three months and year-to-date, indicating solid momentum.
Reasonable Expense Ratio
The ETF's expense ratio is moderate, making it a cost-effective option compared to many actively managed funds.
Negative Factors
Over-Concentration in Health Care
Nearly 90% of the fund is allocated to the health care sector, which could expose investors to sector-specific risks.
Weak Performance from Key Holdings
Some top holdings, like UnitedHealth and Regeneron, have underperformed year-to-date, which may drag on overall returns.
Limited Geographic Diversification
With over 98% exposure to U.S. companies, the ETF lacks international diversification, increasing vulnerability to domestic market conditions.
PINK vs. SPDR S&P 500 ETF (SPY)
AUM353.01M
RegionNorth America
Expense Ratio0.51%
Beta0.61
IssuerSimplify
Inception DateOct 07, 2021
Dividend Yield0.44%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume276,390
30 Day Avg. Volume195,325
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
44.97Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering61
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PINK Summary
The Simplify Health Care ETF (Ticker: PINK) is an investment fund focused on the health care sector, including companies in biotechnology, pharmaceuticals, medical devices, and health care services. It holds well-known companies like UnitedHealth and AbbVie, giving investors exposure to businesses driving innovation and growth in health care. This ETF may appeal to those looking for long-term growth opportunities in a vital and expanding industry. However, new investors should be aware that its performance is closely tied to the health care sector, which can be affected by regulatory changes or market fluctuations.
How much will it cost me?The Simplify Health Care ETF (PINK) has an expense ratio of 0.5%, which means you’ll pay $5 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a specific sector like health care, which requires more research and expertise. It’s designed to give investors targeted exposure to innovative health care companies.
What would affect this ETF?The Simplify Health Care ETF (PINK) could benefit from advancements in biotechnology and pharmaceuticals, as well as increased demand for health care services driven by aging populations and global health awareness. However, it may face challenges from regulatory changes, pricing pressures in the pharmaceutical industry, and potential economic downturns that could impact consumer spending on health care. Its strong U.S. focus and top holdings in companies like UnitedHealth and AbbVie position it well for growth but also expose it to risks tied to U.S. health care policies.
PINK Top 10 Holdings
The Simplify Health Care ETF (PINK) is heavily concentrated in the U.S. health care sector, with biotech and pharmaceuticals leading the charge. Eli Lilly and Regeneron are rising stars, benefiting from strong financial performance and strategic R&D investments, while Amgen offers steady growth despite valuation concerns. On the flip side, PureCycle Technologies and UnitedHealth are dragging the fund, with PureCycle struggling to find its footing amid financial instability and UnitedHealth facing challenges from rising medical costs. Overall, the ETF’s focus on innovation and health care advancements provides a compelling long-term narrative, though near-term volatility persists.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| UnitedHealth | 9.38% | $33.40M | $297.45B | -34.71% | 72 Outperform | |
| Eli Lilly & Co | 7.99% | $28.46M | $939.37B | 29.02% | 72 Outperform | |
| Regeneron | 7.08% | $25.21M | $76.32B | 0.79% | 78 Outperform | |
| Amgen | 5.47% | $19.49M | $169.83B | 15.81% | 77 Outperform | |
| PureCycle Technologies | 5.17% | $18.40M | $1.69B | -21.66% | 38 Underperform | |
| Gilead Sciences | 4.36% | $15.53M | $150.54B | 33.37% | 78 Outperform | |
| Apellis Pharmaceuticals | 3.80% | $13.54M | $3.12B | -23.75% | 50 Neutral | |
| CVS Health | 3.68% | $13.09M | $100.25B | 63.03% | 64 Neutral | |
| Jazz Pharmaceuticals | 3.32% | $11.83M | $10.02B | 33.41% | 64 Neutral | |
| United Therapeutics | 3.30% | $11.74M | $20.88B | 35.09% | 79 Outperform |
PINK Technical Analysis
Positive
―
Price Trends
34.63
Positive
32.49
Positive
30.78
Positive
Market Momentum
0.70
Positive
61.73
Neutral
61.87
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PINK, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 36.88, equal to the 50-day MA of 34.63, and equal to the 200-day MA of 30.78, indicating a bullish trend. The MACD of 0.70 indicates Positive momentum. The RSI at 61.73 is Neutral, neither overbought nor oversold. The STOCH value of 61.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PINK.
PINK Peer Comparison
Comparison Results
Performance Comparison
PINK
Simplify Health Care ETF
37.10
6.91
22.89%
IETC
iShares Evolved US Technology ETF
―
―
―
PWRD
Tcw Transform Systems Etf
―
―
―
FEPI
REX FANG & Innovation Equity Premium Income ETF
―
―
―
RSHO
Tema American Reshoring ETF
―
―
―
IYRI
NEOS Real Estate High Income ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents